Library

Clinical characteristics of newly diagnosed Parkinson’s disease patients included in the longitudinal BIO-PD study

Biomarkers, Pre-PD, Symptoms / Diagnosis /

The frequencies of symptoms and abnormal findings in PD patients were as follows: hyposmia 82.4%, substantia nigra hyperechogenicity 75.4%, history of anxiety or depression disorder 29.5%, constipation 22.1%, and REM (rapid eye movement) sleep behavior disorder 22%. Conclusion: Baseline characteristics of patients enrolled in the BIO-PD study are comparable to other de novo PD cohorts, […]

Clinical characteristics of newly diagnosed Parkinson’s disease patients included in the longitudinal BIO-PD study Read More »

Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial

Butyrate, Pre-PD, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids, Therapies /

Clinically, we observed a reduction in non-motor symptoms load in PD + RS. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in PD + RS. RESISTA-PD highlights that a prebiotic treatment with RS is

Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial Read More »

A narrative review of relationship between gut microbiota and neuropsychiatric disorders: mechanisms and clinical application of probiotics and prebiotics

Gut Microbiota, Probiotics, Prebiotics and Symbiotics, Symptoms / Diagnosis, Therapies /

Current research shows that probiotics and prebiotics have a good preventive effect on Alzheimer’s disease, Parkinson’s disease, depression, autism spectrum disorders and other neurological and mental diseases. Based on this, we review the relevant research on the pathogenesis of probiotics and prebiotics and neuropsychiatric diseases, in an attempt to providing new ideas for exploring the

A narrative review of relationship between gut microbiota and neuropsychiatric disorders: mechanisms and clinical application of probiotics and prebiotics Read More »

Why Researchers Look to Gut Microbial Metabolites in Parkinson’s Disease

Gut Microbiota, Gut Permeability / Leaky Gut, Metabolites, Short Chain Fatty Acids, Symptoms / Diagnosis /

Findings highlight significant differences in the fecal microbiome and metabolome in patients with Parkinson’s disease and control subjects, demonstrating an important connection between the brain and gut that could influence the disease process and progression. CLICK TO REVIEW

Why Researchers Look to Gut Microbial Metabolites in Parkinson’s Disease Read More »

Smell tests to distinguish Parkinson’s disease from other neurological disorders: a systematic review and meta-analysis

Biomarkers, Olfactory, Pre-PD, Symptoms / Diagnosis /

Olfactory impairment has been considered for differential diagnosis in Parkinson’s Disease (PD) patients. The authors aimed to identify the tests used to assess the olfactory function in PD patients and examine these tests’ ability to distinguish them from other neurological disorders. CLICK TO REVIEW

Smell tests to distinguish Parkinson’s disease from other neurological disorders: a systematic review and meta-analysis Read More »

Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial

Diet and Exercise, Pre-PD, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

Our study demonstrates that ITF-prebiotic intake during 3 months decreases a fecal marker of intestinal inflammation in obese patients. Our data point to a potential contribution of microbial lipid-derived metabolites in gastro-intestinal dysfunction related to obesity. CLICK TO REVIEW

Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial Read More »

Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi‐Omics

Biomarkers, Butyrate, Gut Microbiota /

Gut microbiome alterations in Parkinson disease (PD) have been reported repeatedly, but their functional relevance remains unclear. Fecal metabolomics, which provide a functional readout of microbial activity, have scarcely been investigated. We investigated fecal microbiome and metabolome alterations in PD, and their clinical relevance. CLICK TO REVIEW Additional article review (click to review)

Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi‐Omics Read More »

Marker-free imaging of α-Synuclein aggregates in a rat model of
2 Parkinson’s disease using Raman microspectroscopy

A-Synuclein, Biomarkers, Pre-PD /

A hallmark of Parkinson’s disease (PD) is the formation of Lewy bodies in the brain. Lewy bodies are rich in the aggregated form of misfolded α-Synuclein (α-Syn). The brain from PD patients can only be analysed after post-mortem, limiting the diagnosis of PD to the manifestation of motor symptoms. In PD patients and animal models

Marker-free imaging of α-Synuclein aggregates in a rat model of
2 Parkinson’s disease using Raman microspectroscopy Read More »

Advances of Mechanisms-Related Metabolomics in Parkinson’s Disease

Biomarkers, Butyrate, Diet and Exercise, Gut Dysbiosis, Gut Microbiota, Mitochondria, Pre-PD, Short Chain Fatty Acids /

In this review, we briefly summarize recent findings and analyze the application of molecular metabolomics in familial and sporadic PD from genetic mutations, mitochondrial dysfunction, and dysbacteriosis. We also review metabolic biomarkers to assess the functional stage and improve therapeutic strategies to postpone or hinder the disease progression. CLICK TO REVIEW

Advances of Mechanisms-Related Metabolomics in Parkinson’s Disease Read More »